Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response

References

• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–12. doi:10.1182/blood-2004-03-1110.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823–3837. doi:10.1016/j.molimm.2007.06.151.
   PubMed Web of Science ®Google Scholar
• Alderson KL, Sondel PM. Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity. J Biomed Biotechnol. 2011;2011:1–7. doi:10.1155/2011/379123.
   Google Scholar
• Becker PSA, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65(4):477–484. doi:10.1007/s00262-016-1792-y.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–758. doi:10.1182/blood.V99.3.754.
   PubMed Web of Science ®Google Scholar
• Veeramani S, Wang S-Y, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011;118(12):3347–3349. doi:10.1182/blood-2011-05-351411.
   PubMed Web of Science ®Google Scholar
• Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64(13):4664–4669. doi:10.1158/0008-5472.CAN-03-2862.
   PubMed Web of Science ®Google Scholar
• Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol. 2010;38(3):213–221. doi:10.1016/j.exphem.2009.12.007.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol Baltim Md. 2014;192(12):5618–5624. 1950 doi:10.4049/jimmunol.1400288.
   PubMed Web of Science ®Google Scholar
• Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331–342. doi:10.1016/j.immuni.2006.06.013.
   PubMed Web of Science ®Google Scholar
• Morvan M, David G, Sébille V, Perrin A, Gagne K, Willem C, Kerdudou N, Denis L, Clémenceau B, Folléa G, et al. Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immunol. 2008;38(12):3474–3486. doi:10.1002/eji.200838407.
   PubMed Web of Science ®Google Scholar
• Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol Baltim Md. 2007;179(2):854–868. 1950
   PubMed Web of Science ®Google Scholar
• Pittari G, Liu X-R, Selvakumar A, Zhao Z, Merino E, Huse M, Chewning JH, Hsu KC, Dupont B. NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol Baltim Md. 2013;190(9):4650–4660. 1950 doi:10.4049/jimmunol.1202120.
   PubMed Web of Science ®Google Scholar
• Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7(6):753–763. doi:10.1016/S1074-7613(00)80394-5.
   PubMed Web of Science ®Google Scholar
• Tarek N, Le Luduec J-B, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung N-KV, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122(9):3260–3270. doi:10.1172/JCI62749.
   PubMed Web of Science ®Google Scholar
• Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung S-H, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res. 2014;2(9):878–889. doi:10.1158/2326-6066.CIR-13-0158.
   PubMed Web of Science ®Google Scholar
• Lisovsky I, Kant S, Tremblay-mclean A, Isitman G, Kiani Z, Dupuy FP, Gilbert L, Bruneau J, Shoukry NH, Lebouché B, et al. Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. J Leukoc Biol. 2019;105(3):551–563. doi:10.1002/JLB.4A0617-242RRR.
   PubMed Web of Science ®Google Scholar
• Kristensen AB, Kent SJ, Parsons MS, Silvestri G. Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. J Virol. 2018;92(11):11. doi:10.1128/JVI.02146-17.
   Web of Science ®Google Scholar
• Forlenza CJ, Boudreau JE, Zheng J, Le Luduec J-B, Chamberlain E, Heller G, Cheung N-KV, Hsu KC. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(21):2443–2451. doi:10.1200/JCO.2015.64.9558.
   PubMed Web of Science ®Google Scholar
• Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019;7(1):70. doi:10.1186/s40425-019-0538-8.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.2403.
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176. doi:10.1111/bjh.12102.
   PubMed Web of Science ®Google Scholar
• Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, Peterlin P, Garnier A, Béné MC, Cesbron A, et al. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. J Immunol. 2019;202(7):2141–2152. doi:10.4049/jimmunol.1801489.
   PubMed Web of Science ®Google Scholar
• Sun JY, Gaidulis L, Miller MM, Goto RM, Rodriguez R, Forman SJ, Senitzer D. Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping. Tissue Antigens. 2004;64(4):462–468. doi:10.1111/j.1399-0039.2004.00303.x.
   PubMedGoogle Scholar
• Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev. 2002;190(1):40–52. doi:10.1034/j.1600-065X.2002.19004.x.
   PubMed Web of Science ®Google Scholar
• Leppers-van de Straat FG, Van Der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, van de Winkel JG. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods. 2000;242(1–2):127–132. doi:10.1016/S0022-1759(00)00240-4.
   PubMed Web of Science ®Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005;304(1–2):88–99. doi:10.1016/j.jim.2005.06.018.
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599–3608. doi:10.1182/blood-2012-04-425397.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Ivarsson MA, Ljunggren H-G, K-j M, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115(6):1166–1174. doi:10.1182/blood-2009-09-245746.
   PubMed Web of Science ®Google Scholar
• Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol. 2008;20(4):555–563. doi:10.1093/intimm/dxn013.
   PubMed Web of Science ®Google Scholar
• MacFarlane AW, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, Millenson MM, Al-Saleem T, Cohen AD, Campbell KS. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology. 2017;6(7):e1330235. doi:10.1080/2162402X.2017.1330235.
   PubMed Web of Science ®Google Scholar
• Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang Y-W, O’Connell A, Ma J, Jablonski SA, Weiner LM. A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res. 2019;7(2):230–243. doi:10.1158/2326-6066.CIR-18-0266.
   PubMed Web of Science ®Google Scholar
• Kennedy PR, Barthen C, Williamson DJ, Pitkeathly WTE, Hazime KS, Cumming J, Stacey KB, Hilton HG, Carrington M, Parham P, et al. Genetic diversity affects the nanoscale membrane organization and signaling of natural killer cell receptors. Sci Signal. 2019;12(612):612. doi:10.1126/scisignal.aaw9252.
   Web of Science ®Google Scholar
• Clémenceau B, Vivien R, Pellat C, Foss M, Thibault G, Vié H. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. mAbs. 2013;5(4):587–594. doi:10.4161/mabs.25077.
   PubMed Web of Science ®Google Scholar
• Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70(23):9554–9561. doi:10.1158/0008-5472.CAN-10-2211.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Andersson S, Björklund AT, Carlsten M, Schaffer M, Björkström NK, Baumann BC, Michaëlsson J, Ljunggren H-G, Malmberg K-J. Estimation of the Size of the Alloreactive NK Cell Repertoire: studies in Individuals Homozygous for the Group A KIR Haplotype. J Immunol. 2008;181(9):6010–6019. doi:10.4049/jimmunol.181.9.6010.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175(7):1731–1743.e13. doi:10.1016/j.cell.2018.10.014.
   PubMed Web of Science ®Google Scholar
• Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM, Cell-Mediated Antibody-Dependent NK. Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015;6:368. doi:10.3389/fimmu.2015.00368.
   PubMed Web of Science ®Google Scholar
• Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol Baltim Md. 2008;180(9):6392–6401. 1950 doi:10.4049/jimmunol.180.9.6392.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123(5):678–686. doi:10.1182/blood-2013-08-519199.
   PubMed Web of Science ®Google Scholar
• Parham P. Co-evolution of lymphocyte receptors with MHC class I. Immunol Rev. 2015;267(1):1–5. doi:10.1111/imr.12338.
   PubMed Web of Science ®Google Scholar